Leadership
Learn more about our CEO and leadership’s backgrounds to see how they drive for great impact across the medical field.
Jason Hoitt is the chief patient officer at Stoke Therapeutics, where he is responsible for overseeing the company’s global commercial, medical affairs and manufacturing functions.
Jason has more than 20 years of experience successfully planning and executing launch strategies at leading biopharma companies, with a focus on companies making the transition from clinical to commercial stage. Prior to joining Stoke, Jason served as the chief commercial officer at Provention Bio, where he led pre-launch and launch strategy and execution for Tzield® (teplizumab-mzwv), the first medicine approved to address the underlying autoimmune cause of type 1 diabetes. Before that, Jason served as the chief commercial officer at Dova Pharmaceuticals, where he led launch strategy and execution for DOPTELET® (avatrombopag) for chronic immune thrombocytopenia. Prior to Dova, Jason was a member of the commercial leadership team at Insmed Incorporated, serving as a vice president and head of sales. He previously held senior roles in sales, marketing and medical affairs at Sarepta Therapeutics, Vertex Pharmaceuticals and Gilead Sciences.
Jason holds a B.A. from the College of the Holy Cross.